-
Tytuł:
-
Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer.
-
Autorzy:
-
Kim S; Department of Radiation Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
Lee JH; Department of Biostatistics, Yonsei University Wonju College of Medicine, Wonju, Korea.
Cha J; Department of Radiation Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
You SH; Department of Radiation Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
-
Źródło:
-
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group [Int J Hyperthermia] 2021; Vol. 38 (1), pp. 144-151.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : Informa Healthcare
Original Publication: London ; Philadelphia : Taylor & Francis, c1985-
-
MeSH Terms:
-
Hyperthermia, Induced*
Rectal Neoplasms*/therapy
Fluorouracil ; Humans ; Hyperthermia ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Retrospective Studies
-
Contributed Indexing:
-
Keywords: Rectal neoplasms; hyperthermia; lymph node; neoadjuvant therapy; radiotherapy
-
Substance Nomenclature:
-
U3P01618RT (Fluorouracil)
-
Entry Date(s):
-
Date Created: 20210209 Date Completed: 20210705 Latest Revision: 20210705
-
Update Code:
-
20240104
-
DOI:
-
10.1080/02656736.2021.1877837
-
PMID:
-
33557636
-
Purpose: Modulated electro-hyperthermia (mEHT) may enhance the tumor response, although the effectiveness of combined neoadjuvant therapy remains unclear. Therefore, we investigated the role of mEHT with neoadjuvant therapy for locally advanced rectal cancer.
Materials and Methods: Clinical data were analyzed for 120 patients who received neoadjuvant treatment for locally advanced rectal cancer (T3/4 or N+, M0) from May 2012 to December 2017. Capecitabine or 5-fluorouracil was administered along with radiotherapy. Patients were categorized into mEHT group (62 patients) and non-mEHT group (58 patients) depending on whether mEHT was added. Surgery was performed 6-8 weeks after the end of radiotherapy.
Results: The median age was 59 years (range, 33-83). The median radiation dose was significantly less for mEHT group (40 Gy) than for non-mEHT group (50.4 Gy). In mEHT group, 80.7% showed down-staging compared with 67.2% in non-mEHT group. For large tumors of more than 65 cm³ (mean), improved tumor regression was observed in 31.6% of mEHT group compared with 0% of non-mEHT group ( p = .024). The gastrointestinal toxicity rate of mEHT group was 64.5%, which was found to be statistically significantly less than 87.9% of non-mEHT group ( p = .010). The 2-year disease-free survival was 96% for mEHT group and 79% for non-mEHT group ( p = .054).
Conclusion: The overall mEHT group had a comparable response and survival using less radiation dosing compared with standard care; the subgroup with large tumors showed improved efficacy for tumor regression after mEHT.
